People who have had a bout of seasonal or common cold in the past may get some protection from COVID-19, according to a study which suggests that immunity to the disease is likely to last a long time — maybe even a lifetime.

The study, published in the journal mBio, is the first to show that the COVID-19-causing virus, SARS-CoV-2, induces memory B cells, long-lived immune cells that detect pathogens, create antibodies to destroy them and remember them for the future.

The next time that pathogen tries to enter the body, those memory B cells can hop into action even faster to clear the infection before it starts, according to the researchers from the University of Rochester Medical Center (URMC) in the US.

Because memory B cells can survive for decades, they could protect COVID-19 survivors from subsequent infections for a long time, but further research will have to confirm this.

The study is also the first to report cross-reactivity of memory B cells — meaning B cells that once attacked cold-causing coronaviruses appeared to also recognise SARS-CoV-2.

The researchers believe this could mean that anyone who has been infected by a common coronavirus — which is nearly everyone — may have some degree of pre-existing immunity to COVID-19.

“When we looked at blood samples from people who were recovering from COVID-19, it looked like many of them had a pre-existing pool of memory B cells that could recognise SARS-CoV-2 and rapidly produce antibodies that could attack it, said study lead author Mark Sangster, a research professor at URMC.

The findings are based on a comparison of blood samples from 26 people who were recovering from mild to moderate COVID-19 and 21 healthy donors whose samples were collected six to 10 years ago — long before they could have been exposed to COVID-19.

From those samples, the researchers measured levels of memory B cells and antibodies that target specific parts of the Spike protein, which exists in all coronaviruses and is crucial for helping the viruses infect cells.

The Spike protein looks and acts a little different in each coronavirus, but one of its components, the S2 subunit, stays pretty much the same across all of the viruses.

Memory B cells can’t tell the difference between the Spike S2 subunits of the different coronaviruses and attack indiscriminately, the researchers said.

They found that was true for beta-coronaviruses, a subclass that includes two cold-causing viruses as well as SARS, MERS and SARS-CoV-2.

What this study doesn’t show is the level of protection provided by cross-reactive memory B cells and how it impacts patient outcomes, according to the researchers said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor